SCHEMBL5355392

SCHEMBL5355392

CCOC(=O)C(Cl)C(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
GAA P10253 2/20 0.51
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
MAPK1 P28482 1/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KCNJ1 P48048 1/20 0.47
KCNH2 Q12809 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CES1 P23141 1/20 0.46
ATM Q13315 1/20 0.46
CA1 P00915 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27946205 0.87 MAPT (0.54) MAPTALDH1A1KDM4EGAACRHBP
SCHEMBL11371745 0.86 CA12 (0.46) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL28689257 0.85 MAPT (0.53) MAPTALDH1A1KDM4EGAACRHBP
SCHEMBL11361315 0.83 ATM (0.53) MAPTALDH1A1GAASMN1; SMN2MEN1
SCHEMBL11811932 0.82 MAPT (0.54) MAPTALDH1A1KDM4EGAACRHBP
SCHEMBL1970298 0.81 KMT2A (0.44) MAPTALDH1A1GAALMNASMN1; SMN2
SCHEMBL1965917 0.80 SMN1; SMN2 (0.51) MAPTALDH1A1GAAL3MBTL1LMNA
SCHEMBL14571219 0.78 MAPK1 (0.53) MAPTALDH1A1KDM4EGAAL3MBTL1
SCHEMBL1340269 0.78 KMT2A (0.48) MAPTALDH1A1KDM4EGAAMAPK1
SCHEMBL10771702 0.78 MAPT (0.57) MAPTALDH1A1KDM4EGAACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294633-B2 Oxazolo-and furopyrimidines and their use in medicaments against tumors NOVARTIS AG (CH) 2007-11-13 US disclosed
EP-1390371-B1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS NOVARTIS AG (CH) 2006-03-08 EP disclosed
US-20040152892-A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors NOVARTIS AG (CH) 2004-08-05 US disclosed
EP-1390371-A1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS Novartis AG (CH) 2004-02-25 EP disclosed
WO-2002092603-A1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS NOVARTIS AG (CH) 2002-11-21 WO disclosed
US-4336389-A 2-Substituted-4-aryl-5-thiazolecarboxylic acids and their derivatives as safening agents MONSANTO COMPANY (US) 1982-06-22 US disclosed
US-4275200-A CONDENSATION OF CARBAMIC ESTERS WITH X-HALOGEN CARBONYL COMPOUNDS AGFA-GEVAERT, A.G. (DE) 1981-06-23 US disclosed
US-4059447-A Photographic material containing oxazolinone-2 couplers AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152892-A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors DPYD, COXFA4L2, MSH2 MAPT 3299/4885ALDH1A1 122/4885KDM4E 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.